Therapy News and Research

RSS

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia, provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.

7 Jun 2010

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announced today the results of a Phase 1 extension study in metastatic colorectal cancer that showed clinical activity of PLX4032 as a single agent in this hard-to-treat patient population. PLX4032 is a novel, oral small molecule targeting an oncogenic BRAF mutation found in over 50 percent of melanomas, about 10 percent of colorectal cancers and eight percent of all solid tumors.

7 Jun 2010

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Focusing on helping clinicians improve experiences for their patients, GE Healthcare is highlighting an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine, June 5-9, in Salt Lake City.

7 Jun 2010

Endocyte presents interim results from phase II trial of EC145 plus Doxil for platinum-resistant ovarian cancer

Endocyte Inc., a company developing targeted small-molecule drug conjugates, will present results of an interim analysis from a randomized phase II clinical trial in women with platinum-resistant ovarian cancer on Sunday (June 6) during the 46th annual meeting of the American Society of Clinical Oncology in Chicago.

7 Jun 2010

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma.

7 Jun 2010

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. The study results suggest a potentially longer disease-free survival and one-year overall survival in this patient group than reported in previous studies of surgery and adjuvant therapy alone. These data were presented in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2010

Bright light therapy has significant effects on sleep disturbances associated with combat-related PTSD

Bright light therapy has significant effects on sleep disturbances associated with combat-related post-traumatic stress disorder, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

CPAP Therapy increases gray-matter volume in obstructive sleep apnea patients

Obstructive sleep apnea patients had reductions of grey-matter volume at baseline but showed significant grey-matter volume increase after three months of CPAP therapy, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.

7 Jun 2010

Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer

Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).

7 Jun 2010

WA health budget can afford the wigs for cancer patients again

The West Australian government has withdrawn funds allotted for wigs for cancer patients at Sir Charles Gairdner Hospital. Cancer patients typically lose their hair during therapy. The measure was undertaken to cut costs and has been severely criticized by the opposition.

6 Jun 2010

DOE program to develop new imager for improving reliability of cancer therapy using heavy-ion beams

In 2008 the Nuclear Science Division (NSD) of the U.S. Department of Energy's Lawrence Berkeley National Laboratory launched the Applied Nuclear Physics program, headed by NSD's Kai Vetter upon his return to Berkeley after six years with Lawrence Livermore National Laboratory. One of the goals of Applied Nuclear Physics is to take experimental principles and equipment created for basic research and develop them into tools that can address practical needs like cancer therapy and homeland security.

5 Jun 2010

KCI to submit labeling for its products cleared by FDA for home use

Kinetic Concepts, Inc. today announced it is the first manufacturer to commit to submitting labeling for its products used in the home to the Food and Drug Administration as part of the agency's medical device Home Use Initiative. KCI will voluntarily submit labeling for its products cleared by FDA for home use for inclusion in the home use device labeling repository on the FDA's website.

5 Jun 2010

NHLBI stops trial evaluating new approach to reduce risk of recurrent stroke in children with sickle cell anemia

The National Heart, Lung, and Blood Institute (NHLBI) has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment.

5 Jun 2010

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, between 31 and 53 months after beginning oral appliance therapy, the sleep apnea treatment remained effective. Subjective daytime sleepiness, fatigue severity, and quality of life also remained improved.

5 Jun 2010

Researchers assess influence of oral dimensions on MAS treatment success in patients with OSA

According to new research that will receive the Graduate Student Research Award on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the ratio between tongue volume and bony enclosure size in patients with obstructive sleep apnea may help dentists calculate oral appliance treatment success.

5 Jun 2010

US dental school graduates not adequately prepared to screen for sleep disorders

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the majority of U.S. dental schools have not adequately prepared their graduates to screen for sleep disorders, which affect more than 70 million adults in the U.S.

5 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

Celgene reports initial data from investigator-initiated study of REVLIMID

Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.

5 Jun 2010

Therapy News and Research

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Endocyte presents interim results from phase II trial of EC145 plus Doxil for platinum-resistant ovarian cancer

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

Bright light therapy has significant effects on sleep disturbances associated with combat-related PTSD

OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

CPAP Therapy increases gray-matter volume in obstructive sleep apnea patients

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer

WA health budget can afford the wigs for cancer patients again

DOE program to develop new imager for improving reliability of cancer therapy using heavy-ion beams

KCI to submit labeling for its products cleared by FDA for home use

NHLBI stops trial evaluating new approach to reduce risk of recurrent stroke in children with sickle cell anemia

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

Researchers assess influence of oral dimensions on MAS treatment success in patients with OSA

US dental school graduates not adequately prepared to screen for sleep disorders

New clinical research findings on oncology to be highlighted at ASCO 2010

Celgene reports initial data from investigator-initiated study of REVLIMID

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News